Member Info for RayPointer

Hi Ivy
Yes, that is puzzling. Especially so since, with Immunobody, the 2 sets of targets in scov1 and scov2 could presumably have been included in 1 vaccine.

Hi Ivy
I understand that day 113 is not relative to the start day of the trial. It is relative to the date of an individual's first dose of scov1. So each of the 40 patients receive 4 doses (2 of scov1 and 2 of scov2).
The only question I raised is how is the device decided for each patient, does the device alternate for successive patients?
This means that the first patient should have received his/her 1st dose of scov2 as well as the 2 doses of scov1, if that patient is still in the trial.

In fact the 2 ARMS of the study of 20 patients each refer to the 2 pharmajet devices

https://clinicaltrials.gov/ct2/show/NCT05047445
Hi Ivy.
This seems to suggest that dosing of each patient takes place at days 1 and 29 for scov1 and then not before days 113 and 141 for scov2 I.e. 4 doses per patient. That also seems clear from the AGM presentation.
There is no mention of dosing for scov1 having to be complete for all 40 patients before dosing of scov2 takes place or that 20 patients receive scov1 and the other 20 scov2.
In fact, I would have thought all 40 patients will have their own individual day 113 and day 141 meaning all patients have the same dosing intervals, give a day or 2. If this is not so, surely this would lead to difficulties in assessing the data.

I understood that all 40 parents receive 4 jabs, 2 of scov1 and 2 of scov2. The 40 will be split into 2 groups and the 2 groups will use different pharmajet devices.
What isn't clear is whether the first 20 patients will have the jabs administered by device 1 and the remaining 20 by device 2, or whether the 2 devices are alternated for successive patients.

https://coppercowcoffee.com/

This brand!
Copper (cash) cow coffee

Yes, the pipeline is still intact and neither trial has adverse safety events.
Lindy did hint in one of her recent presentations that small biotechs are always at the bottom of the pile when it comes to clinical trials.
We sure are used to waiting though!

Don't forget to add Modi2 into the equation which is pre-clinical now.
Also the glycans mAbs for which there were 3 collaborations.

But I agree that modi1 first patient dosed is likely to be the next news. We might actually see faster recruitment (by SCIB1 standards) since it appears that the chief clinician is very keen to get started.

I recorded an adverse event whilst reading your post Burble.
Only joking :-)

Is Bushey actually a certain politician I ask myself :-)

Any truth in the rumour that Putin is planning strikes on Nottingham and Oxford?

If you go down the cellar at night, you are actually nearer to the sun
#cleverclogs

Hi C7
I should think that Karolinska are going down a different path to that of Lindy with Moditope.
Whereas Lindy is seeking to use citrullinated and homo-citrullinated epitopes as targets to kill cancer cells, Karolinska will be looking to supress the two of then in order to limit auto-immune diseases such as RA.
No doubt Lindy's research will be useful to them in that it perhaps shows the chain of events that causes the immune system to attack healthy cells. Karolinska will presumably be looking for a way to break that chain.

Mick Jagger has something to say about this thread

https://www.youtube.com/watch?v=ncRkWJmRzX8

Not a boring post at all Bermuda, except perhaps to Hasibo :-)

'One peptide, conserved between SARS-CoV and SARS-CoV-2 [35], stimulated a response in cells from immunised HLA-A2 transgenic mice (N 138–146), thereby highlighting the potential of these T cells to recognise other coronaviruses.'

I think this is quite likely to be the peptide that Lindy mentioned in one of her recent presentations as being able to work against the Omicron variant.
With the Immunobody generated T Cells being such high avidity, this one peptide alone may be enough to have a big effect on any variant of Covid19.
If this peptide is indeed conserved for all coronaviruses, then there is no telling how useful a vaccine Covidity will be against the next Coronavirus that we are told is bound to appear at some point.

It's so smart of Lindy to work all this out without the benefit of hindsight and also the many recent articles about the importance of T Cells and also the targeting of the N protein.

Of course, we still await the preliminary data to give us some early indications of the potential of Covidity.

Sorry, forgot the link

https://news.sky.com/story/coronavirus-scientists-warn-government-is-putting-big-bets-on-vaccines-that-may-not-work-12004889

This is what she said

"Dr Charlie Weller, head of vaccines at the Wellcome Trust, said until there is good clinical evidence to back a vaccine it's wise to spread your bets.
The front runners don't necessarily mean they are the best options,
They are the first to get into clinical trial and give us data to understand the different approaches. We will learn a huge amount from them.
But it doesn't mean they are the best. It means they are the first.
Dr Weller said multiple vaccines are likely to be needed that work in different ways to end the pandemic."

Thank you Johnny
As I recall, in the article that Sky TV made about Scancell, Dr Charlie Weller of the Wellcome Trust said a few words about Covid vaccines. She didn't mention Scancell but she must know about them to agree to be part of the article.

Hi Ruck

"So, look at Japan compared to the UK. This is almost certainly down to the fact that Japan has one of the lowest obesity rates in the world whilst the UK has one of the highest"

Judging by what violindog has said in the past with wards filling up with obese patients, this may be the most important factor.

I just think that Lindy has a lot of unfinished business with Immunobody as a cancer vaccine.

Since the original SCIB1 trial, Immunobody has been improved with a much wider range of HLA types, the addition of Avidimab and now the pharmajet injection device. I also think that Lindy really prefers the peptide delivery method and we know that Scancell are sponsoring a PHD in this area at Nottingham Uni. This research could come up trumps in the near future, who knows?

I would think she would want to run at least one Immunobody cancer trial with these improvements before considering a deal for Immunobody as a cancer platform.

Burble, I wonder if Lindy is thinking that, if Covidity lives up to expectations then look for an Immunobody deal on infectious diseases only. CEPI may well be keen on such a deal. That would leave Scancell plenty of time to collect more evidence on SCIB1/2 plus any other SCIBs that Lindy has in mind.